Serialization in Pharmaceuticals
February 27, 2013 | ARCHIVE NOW AVAILABLE
Serialization provides many benefits in addition to regulatory compliance, including improving patient safety, protecting corporate reputation, enhancing corporate social responsibility, and providing a competitive advantage. There is also value in data collected through serialization efforts. Manufacturers are discovering different ways to make best use of the data being returned by their supply chain partners.
Moreover, counterfeiting of drugs and medical devices costs the pharmaceutical and medical device industry billions of dollars annually in lost revenues. This loss is amplified by the serious threats fake drugs pose to the health and safety of consumers.
Join our speaker from Bristol-Myers Squibb, one of the first companies to understand the multiple benefits of item level serialization, as he examines serialization and it use in fighting counterfeit drugs.
A live Q&A session with the audience will follow the presentation.
Mr. Daljeet Sahni, AD Global Supply Chain.
Daljeet Sahni currently works in the Global Supply Chain organization at Bristol-Meyers Squibb and has over 18 years experience in developing and executing strategies across a range of industries including Pharmaceuticals, Financial and Technology. Daljeet has an expert’s view of supply chain management and Serialization as a leader at Bristol-Meyers Squibb. He joined Bristol-Myers Squibb in 2011 to lead two major segments of BMS’s Global Serialization Initiative. Daljeet leads the Data segment, which is responsible for establishing the data governance standards that will guide the Serialization program; and he also leads the Market Regulations segment, implementing a market monitoring process, executed by BMS’s global network of regulatory experts. As Serialization regulations evolve and mature country-to-country, Daljeet establishes BMS’s response and action plans for the Serialization approach in these markets.
Prior to BMS, Daljeet held leadership roles at Merck, Radian, AstraZeneca, Oracle and Bank of America (formerly MBNA). Daljeet has a master’s degree in Computer Science and received his MBA from the University of Delaware.”
Date & Registration Info
|ARCHIVE NOW AVAILABLE
Date : Feb 27, 2013
Who should attend?
|Professionals from pharmaceutical, biotechnology and medical device companies with responsibilities and interests in the following areas:
- Supply Chain Management
- Regulatory Compliance
- State Reporting
- Business Analysis and Development
- Legal and Regulatory Affairs
- Government Affairs
- Sales & Marketing
- Strategic Planning and Operation
- Commercial Operations
Terms and Conditions
Registration entitles the viewer attendance during the live webinar and to the recording of the presentation. If a webinar is cancelled due to unforeseen circumstances, the registrant is entitled to attend the rescheduled webinar or to receive a credit for a future webinar
Copyright 2012 Xtalks Ecademy | Part of Honeycomb Worldwide Inc